Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

M. Wirth; C. Tyrrell; K. Delaere; M Sanchez-Chapado; J. Ramon; Michael Wallace; J. Hetherington; F. Pina; C. Heyns; T. Borchers; T. Morris; J. Armstrong

Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

M. Wirth, C. Tyrrell, K. Delaere, M Sanchez-Chapado, J. Ramon, Michael Wallace, J. Hetherington, F. Pina, C. Heyns, T. Borchers, T. Morris, J. Armstrong

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Original language	English
Pages (from-to)	194-200
Journal	Prostate Cancer and Prostatic Diseases
Volume	8
Publication status	Published - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Wirth, M., Tyrrell, C., Delaere, K., Sanchez-Chapado, M., Ramon, J., Wallace, M., Hetherington, J., Pina, F., Heyns, C., Borchers, T., Morris, T., & Armstrong, J. (2005). Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases, 8, 194-200.

@article{6e7c88d39ca54e8290ba2fc7323be966,

title = "Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme",

author = "M. Wirth and C. Tyrrell and K. Delaere and M Sanchez-Chapado and J. Ramon and Michael Wallace and J. Hetherington and F. Pina and C. Heyns and T. Borchers and T. Morris and J. Armstrong",

year = "2005",

language = "English",

volume = "8",

pages = "194--200",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

}

Wirth, M, Tyrrell, C, Delaere, K, Sanchez-Chapado, M, Ramon, J, Wallace, M, Hetherington, J, Pina, F, Heyns, C, Borchers, T, Morris, T & Armstrong, J 2005, 'Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme', Prostate Cancer and Prostatic Diseases, vol. 8, pp. 194-200.

Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. / Wirth, M.; Tyrrell, C.; Delaere, K. et al.
In: Prostate Cancer and Prostatic Diseases, Vol. 8, 2005, p. 194-200.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

AU - Wirth, M.

AU - Tyrrell, C.

AU - Delaere, K.

AU - Sanchez-Chapado, M

AU - Ramon, J.

AU - Wallace, Michael

AU - Hetherington, J.

AU - Pina, F.

AU - Heyns, C.

AU - Borchers, T.

AU - Morris, T.

AU - Armstrong, J.

PY - 2005

Y1 - 2005

M3 - Article

SN - 1365-7852

VL - 8

SP - 194

EP - 200

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

ER -